Hester Biosciences Limited — Investor Meet, 12-05-2025: Analysts/Institutional Investor Meet/Con. Call Updates

Hester Biosciences reported flat consolidated revenue growth in FY25 due to last year’s one-off pharma exports, with underlying divisional sales rising 12-13%. Q4 standalone profit jumped 17-30%, and consolidated profit grew 36%, driven by efficiency and cost control. Animal Health and Pet Care sales rose 6-8%, led by strong vaccine demand and new therapeutic offerings. The Avian Influenza vaccine launch is expected by Q2 FY26. Hester Africa cut losses significantly, targeting breakeven in 1-2 years. Capex focuses on fill-finish and BSL-3 facilities with commercialization starting Q2 and gradual capacity ramp-up. Management highlighted diversified products and profitable growth across domestic, African, and Asian markets.